By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – PGXL Labs today announced a partnership for the use of AutoGenomics' Infiniti Analyzer for several personal medicine applications.

PGXL plans to use the Infiniti Warfarin assay and the CYP450 assay, both of which have been cleared by the US Food and Drug Administration, as well as the Infiniti KRAS-BRAF test, it said.

AutoGenomics' Infiniti Analyzer is a microarray-based molecular diagnostics platform for measuring multiple signals from clinical samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.